After facing numerous opponents — including the chief justice of the Montana Supreme Court — and no proponents during a ...

An aviation fuel company in Great Falls will soon receive its first installment of a nearly $1.7 billion loan from the ...

The judge said Regier consistently during the 2023 session denied relying on political considerations and told others he didn't know how to check the partisan lean of his proposed districts.

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other ...

(ABC 6 News) – On Monday, Attorney General Keith Ellison announced a settlement with Novo Nordisk that let’s Minnesotans buy its insulin products for $35 per month. For the next five years ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned to the trickier task of finding a way to lose fat while retaining muscle.

Scott Applewhite, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] WASHINGTON (AP) — The Supreme Court on Tuesday turned back an election law case out of Montana that relied ...

It is the largest study ever of the drug category—which includes Novo Nordisk’s GLP-1 treatments Ozempic and Wegovy and Eli Lilly’s dual-action GLP-1/GIP agonists Mounjaro and Zepbound.

Will Medicare end Novo Nordisk's obesity drug boom? It's not surprising that CMS chose Ozempic, Wegovy, and Rybelsus for Medicare drug price negotiations. Between November 2023 and October 2024 ...